Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 17/20 | 0.62 |
| ▸ | ITGAV | P06756 | 17/20 | 0.62 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL725946 | 1.00 | ITGB3 (0.62) | ITGB3ITGAVITGA2B | |
| SCHEMBL7249304 | 0.91 | ITGB3 (0.57) | ITGB3ITGAVITGA2B | |
| SCHEMBL725774 | 0.89 | ITGB3 (0.62) | ITGB3ITGAVITGA2B | |
| SCHEMBL725168 | 0.88 | ITGB3 (0.60) | ITGB3ITGAVITGA2B | |
| SCHEMBL1532143 | 0.88 | ITGB3 (0.54) | ITGB3ITGAVITGA2B | |
| SCHEMBL726173 | 0.87 | ITGB3 (0.62) | ITGB3ITGAVITGA2B | |
| SCHEMBL726398 | 0.86 | ITGB3 (0.57) | ITGB3ITGAVITGA2B | |
| SCHEMBL7363223 | 0.81 | ITGB3 (0.84) | ITGB3ITGAVITGA2B | |
| SCHEMBL727234 | 0.80 | ITGB3 (0.54) | ITGB3ITGAVITGA2B | |
| SCHEMBL725915 | 0.79 | ITGB3 (0.49) | ITGB3ITGAVITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4647791-B2 | — | — | 2011-03-09 | — | — | JP | claimed |
| EP-1171428-B1 | FAB I INHIBITORS | AFFINIUM PHARM INC (CA) | 2009-06-17 | — | — | EP | claimed |
| EP-1171428-A4 | FAB I INHIBITORS | AFFINIUM PHARM INC (CA) | 2004-09-15 | — | — | EP | claimed |
| US-6765005-B2 | BACTERICIDES; ENZYME INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2004-07-20 | — | — | US | claimed |
| US-6503903-B1 | Administering 3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-7-carboxamide derivative | SMITHKLINE BEECHAM CORPORATION | 2003-01-07 | — | — | US | claimed |
| JP-2002542235-A | — | — | 2002-12-10 | — | — | JP | claimed |
| EP-1171428-A1 | FAB I INHIBITORS | SmithKline Beecham Corporation (US) | 2002-01-16 | — | — | EP | claimed |
| WO-2000063187-A1 | FAB I INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-10-26 | — | — | WO | claimed |
| US-20130281442-A1 | Compounds for Treatment of Bovine Mastitis | DEBIOPHARM INTERNATIONAL SA (CH) | 2013-10-24 | — | — | US | disclosed |
| EP-2579863-A2 | COMPOUNDS FOR TREATMENT OF BOVINE MASTITIS | Affinium Pharmaceuticals, Inc. (CA) | 2013-04-17 | — | — | EP | disclosed |
| WO-2011156811-A2 | COMPOUNDS FOR TREATMENT OF BOVINE MASTITIS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2011-12-15 | — | — | WO | disclosed |
| EP-1171428-B1 | FAB I INHIBITORS | AFFINIUM PHARM INC (CA) | 2009-06-17 | — | — | EP | disclosed |
| EP-1171428-A4 | FAB I INHIBITORS | AFFINIUM PHARM INC (CA) | 2004-09-15 | — | — | EP | disclosed |
| US-6765005-B2 | BACTERICIDES; ENZYME INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2004-07-20 | — | — | US | disclosed |
| US-20030139377-A1 | Fab I inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-07-24 | — | — | US | disclosed |
| US-6503903-B1 | Administering 3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-7-carboxamide derivative | SMITHKLINE BEECHAM CORPORATION | 2003-01-07 | — | — | US | disclosed |
| EP-1171428-A1 | FAB I INHIBITORS | SmithKline Beecham Corporation (US) | 2002-01-16 | — | — | EP | disclosed |
| WO-2000063187-A1 | FAB I INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281442-A1 | Compounds for Treatment of Bovine Mastitis | LPO, MPO, MMP8 | ITGB3 1584/4885ITGAV 2813/4885ITGA2B 2410/4885 |
| US-20030139377-A1 | Fab I inhibitors | SERPINB1, TFPI, TFPI2 | ITGB3 1680/4885ITGAV 1554/4885ITGA2B 1135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.